What happened
Shares of rare disease biopharma Horizon Pharma (NASDAQ:HZNP) surged over 13% today after the law firm of Green, Griffith successfully asserted one of the company’s patents covering Pennsaid 2% against a generic challenge from Teva Pharmaceuticals. It’s the company’s top-selling drug, having generated about one-fifth of total revenue in the first half of 2017.
